Malaria vaccine: a potentially big long-term boost

The economic impact of the Oxford malaria vaccine, which has now been approved by regulators in Ghana and Nigeria, will depend on the pace and breadth of the rollout and how long immunity lasts for. But it could potentially have a large positive impact on long-run GDP growth in much of Sub-Saharan Africa where the disease is still prevalent.

In view of the wider interest, we are also sending this Africa Update to clients of our Emerging Markets Economics and Long Run services.